Close Menu

NEW YORK – OpGen said on Wednesday that its subsidiary Curetis has received more than €350,000 ($410,000) from the Federal German Ministry of Education and Research to use artificial intelligence for developing a test for carbapenem resistance in Gram-negative bacteria.

The project includes Curetis, based in Holzgerlingen, Germany, and collaborators at the Research Campus InfectoGnostics and is coordinated by Jena University Hospital. Curetis alone received €350,000 for the project, which is expected to start this month and run until August 2025.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature survey finds a high level of support among scientists for former Vice President Joe Biden in the upcoming US election.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The Scientist reports the physician behind Surgisphere inactivated his medical license in one state and received one in another.

In PLOS this week: analysis of link between somatic copy number and telomere length, sequencing study of individuals with gallbladder S. Typhi colonization, and more.